Accelerating research

and development of

new antibiotics and

alternatives

The Netherlands Antibiotic Development Platform

The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.

NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties. At a later stage, the NADP will provide Drug Discovery Management support/vouchers and Intellectual Property and Technology Transfer Office support.

News

WHO published report on antibacterial agents in clinical development

As part of implementation of the Global Action Plan on Antimicrobial Resistance, WHO drew up a list of priority antibiotic-resistant pathogens (priority pathogens list; PPL) to guide research into and the discovery and development of new antibiotics. Furthermore, the pipeline of antibacterial products that are in clinical development was analyzed.

Read more

British Biotech Receives €52M Boost to Beat Antimicrobial Resistance with New Antibiotic

In a recent press release Summit Therapeutics announced they received the BARDA Contract worth $62 mil. for the development of a new treatment against Clostridium difficile infections.

Read more

Upcoming events

A list of upcoming events, with topics around antimicrobial resistance, development of new antibiotics and alternative therapies.

Read more

Funding Opportunities

A list of funding opportunities, with topics around antimicrobial resistance, development of new antibiotics and alternative therapies.

Read more

NADP Partners

CARES-Logo-150x82
CeSAM-logo-147x82
ImmunoValley-logo-210x82
NCOH-logo-210x82

Supported by

Ministerie-VWS